NCT01256853

Modified Vaccinia Ankara (MVA) Vaccine Study

A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Chinese University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, dose escalation trial of MVA-EBNA1/LMP2 vaccine across a pre-defined range of doses in patients in remission having had an EBV+ nasopharyngeal carcinoma (NPC).

Conditions

• Nasopharyngeal Neoplasms
• Epstein-Barr Virus Infections

Interventions

Type	Name	Description
DRUG	MVA Vaccine	The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.

Timeline

• Start date: 2006-09-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2010-12-09
• Last updated: 2011-12-22

Locations

1 site across 1 country: Hong Kong